Skip to main content
SpringerLink
Log in

Fluvastatin

Clinical and Safety Profile

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Therapy with HMG-CoA reductase inhibitors (statins) has been shown to significantly reduce major coronary events and death in a wide range of individuals at risk for these events. In addition, recent observations suggest that some of the clinical benefits associated with statin therapy may be pleiotropic; that is, independent of their cholesterol-inhibiting action. It is clear that the clinical benefits associated with statin therapy far outweigh the risks; however, there may be important clinical differences among agents within the class, related to both benefits and drug safety. Evaluation of the benefit-to-risk profile for each available statin should include considering the results of randomised clinical outcome trials, the safety record of each agent, effect on lipoproteins and evidence of beneficial pleiotropic properties.

Recently, data from several clinical outcome trials have shown that substantial benefits are associated with treatment with fluvastatin in diverse populations. In particular, data from two large, randomised clinical trials have demonstrated that fluvastatin is effective for secondary prevention of cardiac events in patients following coronary intervention procedures, and for primary prevention of cardiac events in renal transplant recipients. Pleiotropic benefits for fluvastatin have been shown in experimental and clinical studies as well. Fluvastatin was the first statin available as an extended-release product (fluvastatin XL 80mg); both formulations have demonstrated efficacy and safety in a wide range of patients. Taken together, these clinical outcomes and safety data suggest a strong benefit-to-risk; profile for fluvastatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Fig. 2
Fig. 3
Table III
Fig. 4
Table IV
Table V
Table VI

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov 19; 344(8934): 1383–9

    Google Scholar 

  2. Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholester-olemia. N Engl J Med 1995 Nov 16; 333(20): 1301–7

    PubMed  CAS  Google Scholar 

  3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 Oct 3; 335: 1001–9

    PubMed  CAS  Google Scholar 

  4. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 Nov 5; 339(19): 1349–57

    Google Scholar 

  5. Downs JR, Clearfield M, Weis S, et al., for the Air Force/Texas Coronary Atherosclerosis Prevention Study Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. JAMA 1998 May 27; 279(20): 1615–22

    PubMed  CAS  Google Scholar 

  6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul 6; 360(9326): 7–22

    Google Scholar 

  7. Serruys PWJC, de Feyter P, Macaya C, et al., for the Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized, placebocontrolled trial. JAMA 2002 Jun 26; 287(24): 3215–22

    PubMed  CAS  Google Scholar 

  8. Shepherd J, Blauw GJ, Murphy MBG, et al., for the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 Nov 23; 360(9346): 1623–30

    PubMed  CAS  Google Scholar 

  9. Holdaas H, Fellström B, Jardine AG, et al., on behalf of the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003 Jun 14; 361(9374): 2024–31

    PubMed  CAS  Google Scholar 

  10. Sever PS, Dahlöf B, Poulter NR, et al., for the ASCOT Investigators. Prevention of coronary and stroke events with atorvas-tatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial —Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 Apr 5; 361(9364): 1149–58

    PubMed  CAS  Google Scholar 

  11. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999 Dec 22–29; 282(24): 2340–46

    PubMed  CAS  Google Scholar 

  12. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998–3007

    Google Scholar 

  13. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003 Mar 10; 163(5): 553–64

    PubMed  CAS  Google Scholar 

  14. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001 Nov 5; 175(9): 486–9

    PubMed  CAS  Google Scholar 

  15. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis [letter]. N Engl J Med 2002 Feb 14; 346(7): 539–40

    PubMed  Google Scholar 

  16. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2(5): 205–7

    PubMed  Google Scholar 

  17. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003 Apr 2; 289(13): 1681–90

    PubMed  CAS  Google Scholar 

  18. SoRelle R. Baycol withdrawn from market. Circulation 2001 Aug 21; 104(8): E9015–6

    Google Scholar 

  19. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001 Sep; 35(9): 1096–107

    PubMed  CAS  Google Scholar 

  20. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995 Aug 1; 52(15): 1639–43

    PubMed  CAS  Google Scholar 

  21. Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochromes P 450. J Pharmacokinet Biopharm 1996 Oct; 24(5): 461–73

    PubMed  CAS  Google Scholar 

  22. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999 Dec; 84(3): 413–28

    PubMed  CAS  Google Scholar 

  23. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002 Feb; 36(2): 288–95

    PubMed  CAS  Google Scholar 

  24. Prueksaritanont T, Subramanian R, Fang X. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002; 30: 505–12

    PubMed  CAS  Google Scholar 

  25. Kyrklund C, Backman JT, Kivisto KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69: 340–5

    PubMed  CAS  Google Scholar 

  26. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301: 1042–51

    PubMed  CAS  Google Scholar 

  27. Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122–9

    PubMed  CAS  Google Scholar 

  28. Farnier M, Bortolini M, Salko T, et al. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol 2003 Jan 15; 91(2): 238–40

    PubMed  CAS  Google Scholar 

  29. Bellosta S, Ferri N, Bernini F, et al. Non-lipid-related effects of statins. Ann Med 2000 Apr; 32(3): 164–76

    PubMed  CAS  Google Scholar 

  30. Comparato C, Altana C, Bellosta S, et al. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction? Nutr Metab Cardiovasc Dis 2001 Oct; 11(5): 328–43

    PubMed  CAS  Google Scholar 

  31. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990 Feb 1; 343(6257): 425–30

    PubMed  CAS  Google Scholar 

  32. Corsini A, Pazzucconi F, Arnaboldi L, et al. Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 1998 May; 31(5): 773–8

    PubMed  CAS  Google Scholar 

  33. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998 Apr; 137 Suppl.: S101–9

    PubMed  CAS  Google Scholar 

  34. Bellosta S, Ferri N, Arnaboldi L, et al. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 2000 Apr; 23 Suppl. 2: B72–8

    PubMed  Google Scholar 

  35. Ridker PM, Rifai N, Pfeffer MA, et al., for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999 Jul 20; 100(3): 230–35

    PubMed  CAS  Google Scholar 

  36. Shovman O, Levy Y, Gilburd B, et al. Antiinflammatory and immunomodulatory properties of statins. Immunol Res 2002; 25(3): 271–85

    PubMed  CAS  Google Scholar 

  37. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001 Nov; 21(11): 1712–9

    PubMed  CAS  Google Scholar 

  38. Ikeda U, Shimada K. Pleiotropic effects of statins on the vascular tissue. Curr Drug Targets Cardiovasc Haematol Disord 2001 Jun; 1(1): 51–8

    PubMed  CAS  Google Scholar 

  39. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998 May 27; 279(20): 1643–50

    PubMed  CAS  Google Scholar 

  40. Massy ZA, Keane WF, Kasiske BL. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 1996 Jan 13; 347(8994): 102–3

    PubMed  CAS  Google Scholar 

  41. Soma MR, Donetti E, Parolini C, et al. HMG CoA reductase inhibitors: in vivo effects on carotid intimai thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993 Apr; 13(4): 571–8

    PubMed  CAS  Google Scholar 

  42. Baetta R, Camera M, Comparato C, et al. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2002 Apr 1; 22(4): 692–8

    PubMed  CAS  Google Scholar 

  43. Sakaeda T, Takara K, Kakumoto M, et al. Simvastatin and lovastatin, but not pravastatin, interact with MDR 1. J Pharm Pharmacol 2002 Mar; 54(3): 419–23

    PubMed  CAS  Google Scholar 

  44. Rosenson RS, Tangney CC, Schaefer EJ. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis 2001 Apr; 155(2): 463–6

    PubMed  CAS  Google Scholar 

  45. Sindermann JR, Fan L, Weigel KA, et al. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Atherosclerosis 2000 Jun; 150(2): 331–41

    PubMed  CAS  Google Scholar 

  46. Yasunari K, Maeda K, Minami M, et al. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 2001 Jun; 21(6): 937–42

    PubMed  CAS  Google Scholar 

  47. Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000; 7(3): 138–44

    PubMed  CAS  Google Scholar 

  48. Tesfamariam B, Frohlich BH, Gregg RE. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. J Cardiovasc Pharmacol 1999 Jul; 34(1): 95–101

    PubMed  CAS  Google Scholar 

  49. Ridker PM, Rifai N, Pfeffer MA, et al., for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998 Sep 1; 98(9): 839–44

    PubMed  CAS  Google Scholar 

  50. Basso F, Lowe GD, Rumley A, et al. Interleukin-6-174G>C polymorphism and risk of coronary heart disease in West of Scotland Coronary Prevention Study (WOSCOPS). Arterioscler Thromb Vasc Biol 2002 Apr 1; 22(4): 599–604

    PubMed  CAS  Google Scholar 

  51. Fischer V, Johnason L, Heitz F, et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999 Mar; 27(3): 410–6

    PubMed  CAS  Google Scholar 

  52. Tse FL, Nickerson DF, Yardley WS. Binding of fluvastatin to blood cells and plasma proteins. J Pharm Sci 1993 Sep; 82(9): 942–7

    PubMed  CAS  Google Scholar 

  53. Barilla D, Prasad P, Hubert M, et al. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol® XL. Biopharm Drug Dispos 2004 Mar; 25(2): 51–9

    PubMed  CAS  Google Scholar 

  54. Sabia H, Prasad P, Smith HT, et al. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolaemia. J Cardiovasc Pharmacol 2001 May; 37(5): 502–11

    PubMed  CAS  Google Scholar 

  55. Ballantyne CM, Pazzucconi F, Pintó X, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther 2001 Feb; 23(2): 177–92

    PubMed  CAS  Google Scholar 

  56. Bruckert E, Liévre M, Giral P, et al. Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients. Am J Geriatr Cardiol 2003 Jul–Aug; 12(4): 225–31

    PubMed  Google Scholar 

  57. Winkler K, Abletshauser C, Hoffmann MM, et al. Effect of fluvastatin slow-release on low density lipoprotein (LDL) sub-fractions in patients with type 2 diabetes: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab 2002 Dec; 87(12): 5485–90

    PubMed  CAS  Google Scholar 

  58. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997 Aug 1; 80(3): 278–86

    PubMed  CAS  Google Scholar 

  59. Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999 Feb 16; 99(6): 736–43

    PubMed  CAS  Google Scholar 

  60. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999 May; 144(1): 263–70

    PubMed  CAS  Google Scholar 

  61. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999 Jan; 20(1): 58–69

    PubMed  CAS  Google Scholar 

  62. Liem AH, van Boven AJ, Veeger NJ, et al., and the FLuvastatin On Risk Diminishment after Acute Myocardial Infarction Study Group. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 2002 Dec; 23(24): 1931–7

    PubMed  CAS  Google Scholar 

  63. Lefkovits J, Topol EJ. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Prog Cardiovasc Dis 1997 Sep–Oct; 40(2): 141–58

    PubMed  CAS  Google Scholar 

  64. Kleemann A, Eckert S, von Eckardstein A, et al., and the CLAPT Study. Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA: the cholesterol lowering atherosclerosis PTCA trial (CLAPT). Eur Heart J 1999 Oct; 20(19): 1393–406

    PubMed  CAS  Google Scholar 

  65. Weintraub WS, Boccuzzi SJ, Klein JL, et al., and the Lovastatin Restenosis Trial Study Group. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994 Nov; 331(20): 1331–7

    PubMed  CAS  Google Scholar 

  66. Bertrand ME, McFadden EP, Fruchart JC, et al., for the PREDICT Trial Investigators. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1997 Oct; 30(4): 863–9

    PubMed  CAS  Google Scholar 

  67. Benghozi R, Bortolini M, Jia Y, et al. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002 Jan 15; 89(2): 231–3

    PubMed  CAS  Google Scholar 

  68. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001 Jul–Aug; 35(7–8): 908–17

    PubMed  CAS  Google Scholar 

  69. Jacobson TA. Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. Expert Opin Drug Saf 2003 May; 2(3): 269–86

    PubMed  CAS  Google Scholar 

  70. Jardine A, Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. J Clin Pharm Ther 1999 Dec; 24(6): 397–408

    PubMed  CAS  Google Scholar 

  71. Foldes K, Maklary E, Vargha P, et al. Effect of diet and fluvastatin treatment on the serum lipid profile of kidney transplant, diabetic recipients: a 1-year follow up. Transpl Int 1998; 11 Suppl. 1: S65–8

    PubMed  Google Scholar 

  72. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996 Dec 15; 62(11): 1559–64

    PubMed  CAS  Google Scholar 

  73. Holdaas H, Hartmann A, Stenstrom J, et al. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995 Jul 13; 76(2): 102A-6A

    Google Scholar 

  74. Holdaas H, Jardine AG, Wheeler DC, et al. Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int 2001 Nov; 60(5): 1990–7

    PubMed  CAS  Google Scholar 

  75. Malyszko J, Malyszko JS, Brzosko S, et al. Effects of fluvastatin on homocysteine and serum lipids in kidney allograft recipients. Ann Transplant 2002; 7(1): 52–4

    PubMed  CAS  Google Scholar 

  76. Gomez G, Alvarez ML, Errasti P, et al. Fluvastatin in the treatment of hypercholesterolemia in renal transplantation. Transplant Proc 1999 Sep; 31(6): 2326–7

    PubMed  CAS  Google Scholar 

  77. Samuelsson O, Attman PO, Knight-Gibson C, et al. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. Am J Kidney Dis 2002 Jan; 39(1): 67–75

    PubMed  CAS  Google Scholar 

  78. Ichihara A, Hayashi M, Ryuzaki M, et al. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002 Aug; 17(8): 1513–7

    PubMed  CAS  Google Scholar 

  79. Hunninghake DB, Davidson M, Knapp HR, et al., and the Fluvastatin Study Group. An extended-release formulation of fluvastatin 80mg shows greater efficacy, with comparable tolerability, versus immediate-release fluvastatin 40mg for once-daily treatment of primary hypercholesterolaemia. Br J Cardiol 2002 Sep; 9(8): 469–75

    Google Scholar 

  80. Olsson AG, Pauciullo P, Soska V, et al. Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolaemia: a randomized trial. Clin Ther 2001 Jan; 23(1): 45–61

    PubMed  CAS  Google Scholar 

  81. Corsini A. Fluvastatin: effects beyond cholesterol-lowering. J Cardiovasc Pharmacol Ther 2000 Jul; 5(3): 161–75

    PubMed  CAS  Google Scholar 

  82. Kimura M, Kurose I, Russell J, et al. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 1997 Aug; 17(8): 1521–6

    PubMed  CAS  Google Scholar 

  83. Ogata Y, Takahashi M, Takeuchi K, et al. Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy. J Cardiovasc Pharmacol 2002 Dec; 40(6): 907–15

    PubMed  CAS  Google Scholar 

  84. Ito T, Ikeda U, Shimpo M, et al. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Cardiovasc Drugs Ther 2002 Mar; 16(2): 121–6

    PubMed  CAS  Google Scholar 

  85. Corsini A, Pazzucconi F, Pfister P, et al. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet 1996 Dec 7; 348(9041): 1584

    PubMed  CAS  Google Scholar 

  86. Mussoni L, Banfi C, Sironi L, et al. Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. Thromb Haemost 2000 Jul; 84(1): 59–64

    PubMed  CAS  Google Scholar 

  87. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001 Jan; 154(1): 87–96

    PubMed  CAS  Google Scholar 

  88. Yasuhara M, Suzumura K, Tanaka K, et al. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits. Biol Pharm Bull 2000 May; 23(5): 570–4

    PubMed  CAS  Google Scholar 

  89. Bandoh T, Mitani H, Niihashi M, et al. Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J Cardiovasc Pharmacol 2000 Jan; 35(1): 136–44

    PubMed  CAS  Google Scholar 

  90. Hussein O, Schlezinger S, Rosenblat M, et al. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997 Jan 3; 128(1): 11–8

    PubMed  CAS  Google Scholar 

  91. Gheith OA, Sobh MA, Mohamed KE, et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron 2002 Aug; 91(4): 612–9

    PubMed  CAS  Google Scholar 

  92. Inoue T, Hayashi M, Takayanagi K, et al. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. Atherosclerosis 2002 Feb; 160(2): 369–76

    PubMed  CAS  Google Scholar 

  93. Hausberg M, Kosch M, Stam F, et al. Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation. Kidney Int 2001 Apr; 59(4): 1473–9

    PubMed  CAS  Google Scholar 

  94. Hedblad B, Wikstrand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001 Apr 3; 103(13): 1721–6

    PubMed  CAS  Google Scholar 

  95. Haak E, Abletshauser C, Weber S, et al. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis 2001 Apr; 155(2): 395–401

    PubMed  CAS  Google Scholar 

  96. Eichstädt HW, Abletshauser CB, Störk T, et al. Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease. J Cardiovasc Pharmacol 2000 May; 345(5): 735–40

    Google Scholar 

  97. Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Investig Med 2000; 48(3): 183–9

    PubMed  CAS  Google Scholar 

  98. Guethlin M, Kasel AM, Coppenrath K, et al. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 1999 Feb 2; 99(4): 474, 475–81

    Google Scholar 

  99. Ridker PM. Connecting the role of C-reactive protein and statins in cardiovascular disease. Clin Cardiol 2003 Apr; 26 (4 Suppl. 3): III39–44

    PubMed  Google Scholar 

  100. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002 Nov 14; 347(20): 1557–65

    PubMed  CAS  Google Scholar 

  101. Chi DS, Jin FX, Yang SG, et al. Effects of fluvastatin on the levels of C-reactive protein and lipids in patients with hyperlipidemia [in Chinese]. Di Yi Jun Yi Da Xue Xue Bao 2002 Dec; 22(12): 1109–11

    PubMed  Google Scholar 

Download references

Acknowledgements

Editorial assistance was funded by a grant from Novartis Pharmaceuticals. The authors acknowledge the editorial assistance of Risa Denenberg (Advantage Communications) and Kerrie Jara (Baylor College of Medicine).

Dr Corsini has no conflicts of interest or financial disclosure directly relevant to the content of this review. Dr Jacobson has served as a consultant for Novartis and Reliant. Dr Ballantyne has received grant/research support from AstraZeneca, diaDexus, Gene Logic, GlaxoSmithKline, Kos, Merck, Novartis, Pfizer, Reliant, Sankyo Pharma and Schering Plough, has acted as a consultant for AstraZeneca, Bayer, Merck, Novartis, Pfizer, Reliant and Schering Plough, and has been on the Speakers Bureau for AstraZeneca, Bristol Myers-Squibb, Kos, Merck, Novartis, Pfizer, Reliant, Sanofi-Synthelabo and Schering Plough.

Author information

Authors and Affiliations

  1. University of Milan, Milan, Italy

    Alberto Corsini

  2. Emory University School of Medicine, Atlanta, Georgia, USA

    Terry A. Jacobson

  3. Baylor College of Medicine, Houston, Texas, USA

    Christie M. Ballantyne

Authors
  1. Alberto Corsini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Terry A. Jacobson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christie M. Ballantyne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christie M. Ballantyne.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corsini, A., Jacobson, T.A. & Ballantyne, C.M. Fluvastatin. Drugs 64, 1305–1323 (2004). https://doi.org/10.2165/00003495-200464120-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464120-00004

Keywords

Search

Navigation